news
The UJI opens door for assistant health lecturers to lead research groups
The UJI has modified the regulations governing research with the aim of making it possible for assistant health lecturers to lead research groups...
List view / Grid view
Regs & Legs
news
AbCellera expands research collaboration with Teva
Collaboration extends initial partnership and aims to generate lead antibody candidates against membrane targets using AbCellera's antibody discovery platform…
news
Mental health at the forefront of issues for US physician organisations
Six national Physician Assistant (PA) organisations came together this past week to identify how to impact the mental health crisis in the US.
news
New WHO Collaborating Centre for Physical Activity and Health
The University of Zurich is launching a new WHO Collaborating Centre for Physical Activity and Health. The Physical Activity and Health Unit and other groups of the Epidemiology, Biostatistics and Prevention Institute will support the Physical Activity Strategy for the World Health Organization (WHO) European Region.
news
DFG €66 million funding for 15 new research training groups
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 15 new Research Training Groups to further support early research...
news
Wildlife conservation plans must consider Lyme disease risk
Lyme disease – an infection contracted from the bite of an infected tick– is an important emerging disease in the UK, and is increasing in incidence in people in the UK and large parts of Europe and North America.
news
Skin cancer on the rise – diagnosis of two types has increased
New diagnoses for two types of skin cancer increased in recent years, according to a Mayo Clinic-led team of researchers.
news
Preclinical candidate CGRP antagonist has potential as treatment for migraines
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
news
Kymab appoints Dr Sonia Quaratino as Chief Medical Officer
Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
news
Exscientia to collaborate with Sanofi for EUR250mil multiple-product development
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
news
A focus on international regulations on IVD
SMi Group’s 3rd In Vitro Diagnostics conference will be take place on the 14th & 15th of June in London, bringing together global leading experts within the medical industry as they focus on the latest international trends within the field...
news
UK institutes sign global educational partnership with Médecins Sans Frontières
The collaboration focuses on the delivery of an educational programme consisting of a suite of flexible Master’s level professional courses including short ones and a full Master’s programme.
news
EU funds research on biofuels and infectious diseases
Biochemist and physician Professor Ivan Dikic and microbiologist Professor Volker Müller are very honoured that their pioneering research projects have been selected for this substantial financial support.
news
BenevolentAI to partner with medical research charity MRC technology
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
news
Aprea Therapeutics to collaborate with Memorial Sloan Kettering cancer center
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
